New York, Jan 30, 2026, 14:47 EST — Regular session
- AbbVie shares climbed roughly 1% in afternoon trading.
- Investors are bracing for results on Feb. 4, along with new guidance for 2026.
- Botox pricing risk and aesthetics data from Paris have returned to the forefront for traders.
AbbVie shares climbed roughly 1% on Friday, closing in on the session peak at $222.73 after fluctuating between $219.54 and $222.77.
The drugmaker plans to release its full-year and Q4 2025 results on Feb. 4 before the market opens, with a webcast set for 8 a.m. Central time. Investors expect the company to provide its first detailed outlook for 2026 in that report. (AbbVie News Center)
A Nasdaq article from Zacks Equity Research highlighted Wall Street’s consensus, projecting quarterly earnings of $2.66 per share on $16.36 billion in revenue. The report zeroed in on key product lines, with analysts estimating Botox Therapeutic sales around $996 million, U.S. Humira revenue near $575 million, and Imbruvica close to $715 million. (Nasdaq)
AbbVie’s stock wavered this week, dropping 2.35% on Wednesday to finish at $218.67. That ended its run of five straight days gaining ground. (MarketWatch)
Pricing factors into the equation. The Centers for Medicare & Medicaid Services, which oversees Medicare, recently listed Botox among 15 drugs slated for upcoming price negotiations under the Inflation Reduction Act. This process aims to lower what Medicare pays for certain medicines. “We continue to expect that the impacts will be manageable,” said Evan Seigerman of BMO Capital Markets. (Reuters)
Allergan Aesthetics, part of AbbVie, announced it will share new facial injectable data at the IMCAS World Congress from Jan. 29–31. This includes pooled Phase 3 results for trenibotulinumtoxinE, a next-gen neurotoxin currently under regulatory review. “Allergan Aesthetics is driving the future of aesthetic medicine,” said John Maltman, vice president of global aesthetics medical affairs. (AbbVie News Center)
Goldman Sachs held its neutral rating and maintained a $223 price target on the stock ahead of earnings. The firm highlighted investor concerns about competitive pressure weighing on growth drivers Skyrizi and Rinvoq, with greater attention on management’s remarks about 2026. (Investing)
The week ahead could swing either way. If guidance disappoints or investors rethink the drug-pricing outlook for Botox, the stock could lose momentum fast.
Looking ahead, the market’s focus is clear: AbbVie’s Feb. 4 earnings report, along with the initial outlook for 2026. Expect detailed sales trends by product to take center stage during the update.
